Griffith & Werner Inc. Invests $2.64 Million in AbbVie Inc.

The investment firm acquired a new stake in the pharmaceutical company's shares.

Published on Mar. 4, 2026

Griffith & Werner Inc., a hedge fund, acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the third quarter, according to the company's recent SEC filing. The firm purchased 12,046 shares of AbbVie's stock, valued at approximately $2.64 million. AbbVie now comprises 1.4% of Griffith & Werner's holdings, making it the 26th largest position in the fund's portfolio.

Why it matters

This investment highlights the continued interest and confidence in AbbVie from institutional investors. As a major pharmaceutical company with a diverse product portfolio, AbbVie's stock has been a popular choice for hedge funds and other institutional investors looking to gain exposure to the healthcare sector.

The details

According to the SEC filing, Griffith & Werner Inc. purchased the 12,046 shares of AbbVie in the third quarter. This new stake represents approximately 1.4% of the firm's total holdings, making AbbVie the 26th largest position in the fund's portfolio. The shares were valued at around $2.64 million at the time of purchase.

  • Griffith & Werner Inc. acquired the new stake in AbbVie Inc. in the third quarter of 2026.

The players

Griffith & Werner Inc.

A hedge fund that recently acquired a new stake in shares of AbbVie Inc.

AbbVie Inc.

A global, research-driven biopharmaceutical company that focuses on discovering, developing, and commercializing therapies for complex and often chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This investment by Griffith & Werner Inc. demonstrates the continued appeal of AbbVie's stock among institutional investors. As a major player in the pharmaceutical industry, AbbVie's diverse product portfolio and strong financial performance have made it a attractive option for hedge funds and other investment firms looking to gain exposure to the healthcare sector.